Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 3/20 | 0.73 |
| ▸ | BLM | P54132 | 5/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | RECQL | P46063 | 3/20 | 0.65 |
| ▸ | APEX1 | P27695 | 3/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Normetanephrine SCHEMBL29516838 | 0.84 | NFKB1 (1.00) | NFKB1BLMPMP22TDP1KDM4E | |
| Normetanephrine SCHEMBL4949341 | 0.84 | NFKB1 (1.00) | NFKB1BLMPMP22TDP1KDM4E | |
| Normetanephrine SCHEMBL137755 | 0.84 | NFKB1 (1.00) | NFKB1BLMPMP22TDP1KDM4E | |
| Normetanephrine SCHEMBL1168235 | 0.83 | BLM (1.00) | NFKB1BLMPMP22TDP1KDM4E | |
| SCHEMBL7151218 | 0.81 | NFKB1 (0.71) | NFKB1BLMPMP22TDP1KDM4E | |
| Normetanephrine SCHEMBL15421560 | 0.81 | NFKB1 (0.94) | NFKB1BLMPMP22TDP1KDM4E | |
| SCHEMBL249737 | 0.81 | NFKB1 (0.71) | NFKB1BLMPMP22TDP1KDM4E | |
| SCHEMBL4849450 | 0.81 | NFKB1 (0.71) | NFKB1BLMPMP22TDP1KDM4E | |
| SCHEMBL7147014 | 0.81 | NFKB1 (0.71) | NFKB1BLMPMP22TDP1KDM4E | |
| SCHEMBL4542685 | 0.80 | NFKB1 (0.69) | NFKB1BLMPMP22TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315493-A4 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | UNIV GEORGETOWN (US) | 2007-12-05 | — | — | EP | claimed |
| US-20050131051-A1 | 2-3-disubstituted quinuclidiness as modulators of monoamine transporters and theraperutic and diagnostic methods based thereon | WANG SHAOMENG (US) | 2005-06-16 | — | — | US | claimed |
| EP-1315493-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2003-06-04 | — | — | EP | claimed |
| WO-2002015906-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2002-02-28 | — | — | WO | claimed |
| CN-119100941-A | Preparation and application of contracture medicine with synergistic antidepressant effect and composition thereof | 江苏海洋大学 | 2024-12-10 | — | — | CN | disclosed |
| CN-115385914-B | Application of ligand small molecule of targeting PDCD4 in preparation of antidepressant drugs | 山东大学 | 2024-04-30 | — | — | CN | disclosed |
| WO-2022246930-A1 | APPLICATION OF LIGAND SMALL MOLECULE TARGETING PDCD4 IN PREPARATION OF ANTIDEPRESSANT DRUGS | 山东大学 | 2022-12-01 | — | — | WO | disclosed |
| CN-115385914-A | Application of ligand small molecule of targeting PDCD4 in preparation of antidepressant drugs | 山东大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-109497342-A | It is a kind of for preventing and treating the feed addictive of chicken diarrhea | 鼎正动物药业（天津）有限公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-101301283-B | Composition transferred through nose and brain containing milnacipran | SHANGHAI INST PHARM INDUSTRY | 2011-04-06 | — | — | CN | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| CN-101194982-B | Anti-depression traditional Chinese medicine composition and preparation method thereof | XUANWU HOSPITAL OF CAPITAL UNIVERSITY OF MEDICAL SCIENCE | 2010-05-19 | — | — | CN | disclosed |
| WO-2005068447-A1 | PIPERAZINE DERIVATIVES WHICH EXHIBIT ACTIVITY AS SEROTONIN AND NORADRENALINE RE-UPATKE INHIBITORS | PFIZER LIMITED (GB) | 2005-07-28 | — | — | WO | disclosed |
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2005-06-23 | — | — | US | disclosed |
| US-20050131051-A1 | 2-3-disubstituted quinuclidiness as modulators of monoamine transporters and theraperutic and diagnostic methods based thereon | WANG SHAOMENG (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2004110995-A1 | N-PYRROLIDIN-3-YL-AMIDE DERIVATIVES AS SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| CN-1539497-A | Combinaton of medication for treating depression and preparation method | �Ϻ���ͨ��ѧ | 2004-10-27 | — | — | CN | disclosed |
| EP-1315493-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2003-06-04 | — | — | EP | disclosed |
| CN-1401381-A | Antidepressant composition and preparation method thereof | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2003-03-12 | — | — | CN | disclosed |
| WO-2002015906-A1 | 2-3-DISUBSTITUTED QUINUCLIDINES AS MODULATORS OF MONOAMINE TRANSPORTERS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON | GEORGETOWN UNIVERSITY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137229-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | AOC3, ADRB3, HTR3C | NFKB1 3512/4885BLM 4285/4885PMP22 3485/4885 |
| US-20050131051-A1 | 2-3-disubstituted quinuclidiness as modulators of monoamine transporters and theraperutic and diagnostic methods based thereon | SLC6A3, SLC6A2, SLC6A4 | NFKB1 3660/4885BLM 4683/4885PMP22 1508/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | NFKB1 2032/4885BLM 998/4885PMP22 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.